bioRxiv (Cold Spring Harbor Laboratory) · 2020 · 141 citations · 34 references
Life SciencesImmunologyInfectious DiseasesAdaptive ImmunityImmunology Of Infectious DiseasesVaccinologyAntibody CharacterizationAntibody-antigen RecognitionAntigen RecognitionB-cell ResponsesHumoral ImmunityImmunological MemoryAntibodiesAntibody-mediated Viral NeutralizationAntibody-mediated Virus NeutralizationB-cell EpitopesConvergent Antibody ResponsesHumoral Immune MemoryNeutralizing Antibody ResponsesSars-cov-2 Infection
Abstract During the COVID-19 pandemic, SARS-CoV-2 infected millions of people and claimed hundreds of thousands of lives. Virus entry into cells depends on the receptor binding domain (RBD) of the SARS-CoV-2 spike protein (S). Although there is no vaccine, it is likely that antibodies will be essential for protection. However, little is known about the human antibody response to SARS-CoV-2 1–5 . Here we report on 149 COVID-19 convalescent individuals. Plasmas collected an average of 39 days after the onset of symptoms had variable half-maximal neutralizing titers ranging from undetectable in 33% to below 1:1000 in 79%, while only 1% showed titers >1:5000. Antibody cloning revealed expanded clones of RBD-specific memory B cells expressing closely related antibodies in different individuals. Despite low plasma titers, antibodies to three distinct epitopes on RBD neutralized at half-maximal inhibitory concentrations (IC 50 s) as low as single digit ng/mL. Thus, most convalescent plasmas obtained from individuals who recover from COVID-19 do not contain high levels of neutralizing activity. Nevertheless, rare but recurring RBD-specific antibodies with potent antiviral activity were found in all individuals tested, suggesting that a vaccine designed to elicit such antibodies could be broadly effective.
34
cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination
Ali Punjani, John L. Rubinstein, David J. Fleet et al. · Nature Methods · 2017 · 10.7K citations
Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
Alexandra C. Walls, Young‐Jun Park, M. Alejandra Tortorici et al. · Cell · 2020 · 9.1K citations · Full text